These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31624794)

  • 1. Low-dose immune tolerance induction for children with hemophilia A with poor-risk high-titer inhibitors: A pilot study in China.
    Li Z; Chen Z; Cheng X; Wu X; Li G; Zhen Y; Cai S; Poon MC; Wu R
    Res Pract Thromb Haemost; 2019 Oct; 3(4):741-748. PubMed ID: 31624794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success.
    Elalfy M; Elghamry I; Hassab H; Elalfy O; Andrawes N; El-Ekiaby M
    Haemophilia; 2022 Jan; 28(1):65-72. PubMed ID: 34797008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors.
    Li Z; Chen Z; Liu G; Cheng X; Yao W; Huang K; Li G; Zhen Y; Wu X; Cai S; Poon MC; Wu R
    Res Pract Thromb Haemost; 2021 Jul; 5(5):e12562. PubMed ID: 34278191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study.
    Escuriola Ettingshausen C; Vdovin V; Zozulya N; Svirin P; Andreeva T; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Zupancic-Šalek S; Pavlova A; Bátorová A; Montaño Mejía C; Abdilova G; Knaub S; Jansen M; Lowndes S; Belyanskaya L; Walter O; Oldenburg J;
    TH Open; 2022 Apr; 6(2):e124-e134. PubMed ID: 35707623
    [No Abstract]   [Full Text] [Related]  

  • 5. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.
    Santagostino E
    Haemophilia; 2013 Jan; 19 Suppl 1():8-11. PubMed ID: 23278994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
    Gringeri A; Musso R; Mazzucconi MG; Piseddu G; Schiavoni M; Pignoloni P; Mannucci PM;
    Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor-titer below 200 BU/mL.
    Li Z; Sun J; Li Z; Chen Z; Liu G; Yao W; Cheng X; Li G; Zhen Y; Ai D; Zhou Y; Mao Q; Poon MC; Wu R
    Pediatr Investig; 2024 Jun; 8(2):91-100. PubMed ID: 38910855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
    Unuvar A; Kavakli K; Baytan B; Kazanci E; Sayli T; Oren H; Celkan T; Gursel T
    Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
    Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
    J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.
    Oldenburg J; Jiménez-Yuste V; Peiró-Jordán R; Aledort LM; Santagostino E
    Haemophilia; 2014 Jan; 20(1):83-91. PubMed ID: 24354480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?
    Ettingshausen CE; Kreuz W
    Haemophilia; 2013 Jan; 19 Suppl 1():12-7. PubMed ID: 23278995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradication of FIX inhibitor in haemophilia B children using low-dose immune tolerance induction with rituximab-based immunosuppressive agent(s) in China.
    Li Z; Liu G; Yao W; Chen Z; Li G; Cheng X; Zhen Y; Ai D; Huang K; Sun J; Poon MC; Wu R
    Haemophilia; 2022 Jul; 28(4):625-632. PubMed ID: 35503087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.
    Kurth M; Puetz J; Kouides P; Sanders J; Sexauer C; Bernstein J; Gruppo R; Manco-Johnson M; Neufeld EJ; Rodriguez N; Wicklund B; Quon D; Aledort L
    J Thromb Haemost; 2011 Nov; 9(11):2229-34. PubMed ID: 21883884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose immune tolerance induction therapy in severe hemophilia a children in China: Starting earlier resulted in better inhibitor eradication outcomes.
    Li Z; Sun J; Li Z; Chen Z; Liu G; Yao W; Li G; Zhen Y; Cheng X; Ai D; Huang K; Poon MC; Wu R
    Thromb Res; 2023 May; 225():33-38. PubMed ID: 36934482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune tolerance induction in patients with severe hemophilia A with inhibitors.
    Ryu JE; Park YS; Yoo KY; Lee KD; Choi YM
    Blood Res; 2015 Dec; 50(4):248-53. PubMed ID: 26770953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.
    Lin PC; Liao YM; Tsai SP; Chang TT
    Pediatr Blood Cancer; 2011 Dec; 57(6):1029-33. PubMed ID: 21793191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune tolerance induction in patients with hemophilia A.
    Astermark J
    Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose Immune Tolerance Induction in Hemophilia: A Single-Center Experience.
    Zulfikar B; Koc B; Ozdemir N
    J Pediatr Hematol Oncol; 2019 Aug; 41(6):e355-e358. PubMed ID: 31343592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE), with or without immunosuppression, in Australian paediatric severe haemophilia A patients with high titre inhibitors: a multicentre, retrospective study.
    Robertson JD; Higgins P; Price J; Dunkley S; Barrese G; Curtin J
    Thromb Res; 2014 Nov; 134(5):1046-51. PubMed ID: 25267706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.